BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nuvilex, Johnson & Johnson (JNJ) and Medtronic, Inc. (MDT), All Developing Type of Artificial Pancreas for Diabetics


7/2/2013 10:11:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, NY--(Marketwired - July 02, 2013) - While Medtronic, Inc. and Johnson & Johnson are developing devices that can essentially act as a type of "artificial pancreas," Nuvilex, Inc.'s (OTCQB: NVLX) unique cell encapsulation technology has shown it too can develop a type of "artificial pancreas" in preclinical diabetes studies. Their approaches couldn't be more different; however, all three companies are convinced that developing an artificial pancreas offers diabetics the best solution to independently monitor their blood sugar levels, and in turn, provide them with insulin when needed.

At the end of June, both Medtronic and Johnson & Johnson presented results from separate studies using their medical insulin pumps at the American Diabetes Association meeting in Chicago. The idea behind the "smart" pumps is to mimic a healthy pancreas by offering diabetics a type of artificial pancreas that can successfully monitor changes in blood sugar levels and then adjust the insulin being delivered to the diabetic in response to those changes.

As the two NYSE-traded companies turn to medical devices to act as their brand of artificial pancreas, the small, Silver Spring, Maryland-based biotech, Nuvilex, is turning to a much smaller and different option -- transplanted living, insulin-producing cells enclosed in capsules about the size of the head of a pin, that form a bundle and act as a miniature cell factory that produces insulin upon demand inside the diabetic's body.

According to the International Diabetes Federation, 371 million people around the world have been diagnosed with diabetes and another 187 million remain undiagnosed. As the number of diagnosed diabetics around the world grows, so too does the market for a solution. By 2020, the market for diabetes medicines and treatments is projected to reach $65 billion worldwide.

Continue reading this article at www.stockmarketmediagroup.com/features.

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors to become better informed on small cap companies. For more information: www.stockmarketmediagroup.com


Contact:
Stock Market Media Group
Email Contact
(646) 397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES